Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14717053 | 0.99 | SYK (0.82) | SYKJAK2 | |
| Hydrochloric Acid SCHEMBL30604800 | 0.99 | SYK (0.82) | SYKJAK2 | |
| SCHEMBL14720095 | 0.91 | SYK (1.00) | SYKJAK2 | |
| SCHEMBL14717020 | 0.91 | SYK (1.00) | SYKJAK2 | |
| Hydrochloric Acid SCHEMBL14716610 | 0.90 | SYK (0.98) | SYKJAK2 | |
| Hydrochloric Acid SCHEMBL29635067 | 0.90 | SYK (0.98) | SYKJAK2 | |
| SCHEMBL14725195 | 0.90 | SYK (1.00) | SYKJAK2 | |
| Hydrochloric Acid SCHEMBL29635122 | 0.89 | SYK (0.98) | SYKJAK2 | |
| Hydrochloric Acid SCHEMBL14716755 | 0.89 | SYK (0.98) | SYKJAK2 | |
| SCHEMBL14725197 | 0.89 | SYK (0.84) | SYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3392252-B1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | LIBERTAS BIO INC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-2748166-B1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF | ASANA BIOSCIENCES LLC (US) | 2018-07-11 | — | — | EP | claimed |
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3392252-B1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | LIBERTAS BIO INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ABS DEVELOPMENT 1, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10647720-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | Asan BioSciences, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190092779-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | Libertas Bio, Inc. | 2019-03-28 | — | — | US | disclosed |
| US-20190070182-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC | 2019-03-07 | — | — | US | disclosed |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | ASANA BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-2748166-B1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF | ASANA BIOSCIENCES LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20160257691-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | Libertas Bio, Inc. | 2016-09-08 | — | — | US | disclosed |
| US-9382277-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382277-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140221315-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2013028818-A1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | ENDO PHARMACEUTICALS INC. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | SYK 741/4885JAK2 139/4885 |
| US-20190070182-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | SYK 919/4885JAK2 350/4885 |
| US-20160257691-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | SYK 741/4885JAK2 139/4885 |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | MKI67, DPYD, TYMP | SYK 919/4885JAK2 350/4885 |
| US-20190092779-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | SYK 741/4885JAK2 139/4885 |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | SYK 741/4885JAK2 139/4885 |
| US-20140221315-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | SYK 741/4885JAK2 139/4885 |
| US-10647720-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | SYK 741/4885JAK2 139/4885 |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | SYK 741/4885JAK2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.